The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 22, 2022

Filed:

Nov. 30, 2018
Applicant:

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Bradley L. Pentelute, Cambridge, MA (US);

Faycal Touti, Cambridge, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/64 (2006.01); A61K 38/00 (2006.01); C07K 1/22 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); G01N 33/68 (2006.01); A61P 35/00 (2006.01); C40B 30/04 (2006.01); A61P 31/12 (2006.01);
U.S. Cl.
CPC ...
C07K 7/64 (2013.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C07K 1/22 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C40B 30/04 (2013.01); G01N 33/6845 (2013.01); G01N 33/6848 (2013.01); A61K 38/00 (2013.01); G01N 2500/20 (2013.01);
Abstract

The present invention provides novel peptides (e.g., peptides, macrocyclic peptides, mini-proteins) that modulate protein-protein interactions or salts thereof, and methods of making and using the inventive peptides. In some embodiments, the peptides are high affinity inhibitors (e.g., Kof at most 100 nM, at most 10 nM, at most 1 nM) of a protein-protein interaction. In certain embodiments, these peptides interfere with p53-MDM2 binding interactions (e.g., by binding to MDM2 (GenBank® Gene ID: 4193)). In some embodiments, the peptides interfere with the dimerization of the C-terminal domain of the human immunodeficiency virus (HIV) capsid protein (C-CA), comprising residues 146-231 of the HIV capsid protein (e.g., by binding to the C-terminal domain of the HIV capsid protein (C-CA), thereby inhibiting the dimeric interface of HIV capsid protein, thereby inhibiting viral assembly). These inventive peptides were rapidly generated and identified using novel methods described herein comprising combinatorial peptide synthesis and/or solution affinity selection.


Find Patent Forward Citations

Loading…